{"name":"APOGEPHA Arzneimittel GmbH","slug":"apogepha-arzneimittel-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Mictonetten 5 mg, coated tablet","genericName":"Mictonetten 5 mg, coated tablet","slug":"mictonetten-5-mg-coated-tablet","indication":"Overactive bladder with symptoms of urinary urgency, frequency, and incontinence","status":"phase_3"},{"name":"propiverine hydrochloride","genericName":"propiverine hydrochloride","slug":"propiverine-hydrochloride","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Mictonetten 5 mg, coated tablet","genericName":"Mictonetten 5 mg, coated tablet","slug":"mictonetten-5-mg-coated-tablet","phase":"phase_3","mechanism":"Mictonetten is a muscarinic M3 receptor antagonist that reduces bladder muscle contractions to treat overactive bladder symptoms.","indications":["Overactive bladder with symptoms of urinary urgency, frequency, and incontinence"],"catalyst":""},{"name":"propiverine hydrochloride","genericName":"propiverine hydrochloride","slug":"propiverine-hydrochloride","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxNWVNiSjlNVl9yRUh2UDV5eTNLeE5uN3E4LXg3LUtOZ21wUHJRVWN2SWdWZngzaWI1T3lEalRTbGZDblR1cE5ILTZyZjRPQ0l4SXBSU085bGdXUFQzYV92T0NIejNHakV4TGhONEVTWUdJUWxtVVNfYV9KbGNUd0VScmpkTDhKd01ULWh4X1E2VmNLWXF3QlN4dUxyMFdEM2o0aTAwWXpVb1owcFE1dTNsdVBFb1ltRGFtVDFOT0ZuQURMRGVPeGpBU1RfV2NjckpJS19Xdk5hSGpNOFZ2NGFFOW1PWU95d3hnNjBOOW93?oc=5","date":"2025-09-16","type":"deal","source":"businesswire.com","summary":"Minze Health and Apogepha Enter Strategic Collaboration to Develop Digital Therapeutic for Male LUTS - businesswire.com","headline":"Minze Health and Apogepha Enter Strategic Collaboration to Develop Digital Therapeutic for Male LUTS","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}